Hirendra Doshi, MD
Gastroenterology · Raleigh, NCNPI 1356312664
Payments from drug & device makers
Across 667 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$1K
- Gilead$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$497
- plus $3K from 28 others
What the payments were for
- Food & beverage$11,02498%
- Education$831%
- Gifts$1251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 153 | $2,456 |
| Pfizer | 108 | $1,481 |
| Gilead | 67 | $1,134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 64 | $1,095 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 61 | $1,093 |
| Johnson & Johnson(2 entities) | 25 | $497 |
| Merck | 22 | $368 |
| Bristol Myers Squibb | 19 | $356 |
| QOL Medical, LLC | 13 | $253 |
| Ferring Pharmaceuticals Inc. | 15 | $237 |
| Redhill Biopharma Inc. | 14 | $220 |
| Intercept Pharmaceuticals, Inc. | 12 | $201 |
| Braintree Laboratories, Inc. | 9 | $191 |
| Ardelyx, Inc. | 10 | $190 |
| Amgen | 11 | $189 |
| Lilly USA, LLC | 7 | $168 |
| Phathom Pharmaceuticals, Inc. | 8 | $138 |
| UCB, Inc. | 8 | $130 |
| Aimmune Therapeutics, Inc. | 6 | $113 |
| Daiichi Sankyo Inc. | 7 | $113 |
| Nestle Healthcare Nutrition Inc. | 6 | $102 |
| Janssen Scientific Affairs, LLC | 1 | $100 |
| Madrigal Pharmaceuticals | 3 | $70 |
| Fresenius Kabi USA, LLC | 4 | $65 |
| Sanofi | 2 | $52 |
| Organon | 3 | $49 |
| Intra-sana Laboratories | 1 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Mirum Pharmaceuticals, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $19 |
| Medtronic | 1 | $19 |
| Dova Pharmaceuticals | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,232 in reported general payments places this provider in the 75th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 19 | $128,760 |
| LinzessLinaclotide | 86 | $64,779 |
| Mesalamine | 59 | $29,261 |
| Dexlansoprazole DrDexlansoprazole | 58 | $18,650 |
| VemlidyTenofovir Alafenamide | 13 | $17,248 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 194 | $12,059 |
| TrulancePlecanatide | 19 | $10,529 |
| Dicyclomine Hcl | 155 | $4,735 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 278 | $4,440 |
| Lubiprostone | 17 | $4,207 |
| Pantoprazole Sodium | 340 | $4,206 |
| Mercaptopurine | 23 | $2,808 |
| Ondansetron OdtOndansetron | 48 | $2,689 |
| Tenofovir Disoproxil Fumarate | 11 | $2,011 |
| Mesalamine ErMesalamine | 12 | $1,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,456 | $64,77986 claims |
| GileadVemlidy | $1,134 | $17,24813 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $1,093 | $10,52919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Raleigh
- Angela HiraRaleigh$513K
- Charles BarishRaleigh$185K
- Evan DellonChapel Hill$11.2M
- Andrew MuirDurham$6.6M
- Manal AbdelmalekDurham$5.6M
- Robert ReindollarSalisbury$2.5M
- John PoulosFayetteville$2.1M
- Hans HerfarthChapel Hill$2M
- Herbert BonkovskyWinston Salem$1.7M
- Ikechukwu IbegbuJacksonville$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.